Password Protected

Please enter your password to continue:

You are now leaving Adalimumabfkjp, a Biocon Biologics website. The website you are about to access is not owned or controlled by Biocon Biologics Inc.

Biocon Biologics Inc. assumes no responsibility for and makes no warranties or representation of any kind as to the accuracy, currency, or completeness any information contained in such third-party website, including any third-party social media or mobile application platform. Inclusion of any third-party link on this website does not imply an endorsement or recommendation by Biocon Biologics, and a link to this website from another website does not imply a relationship between Biocon Biologics and any third party. Your use of any such third-party site or platform is at your own risk and will be governed by such third party’s terms and policies (including its privacy policy). Biocon Biologics shall not be liable for any direct, indirect, consequential, incidental or punitive damages arising out of access to, use of, or inability to use such third-party website, or any errors or omissions in the content thereof.

OK
CANCEL

You are now departing from the Adalimumabfkjp website and redirected to the Biocon Biologics corporate website. Please be aware that the Biocon Biologics corporate website may contain information that varies from the content on the Adalimumabfkjp website. The website you are about to access is the corporate website, located outside the U.S.
U.S. regulations may not be applicable to the content on this corporate website.

OK
CANCEL
The information contained in this section of the site is intended for US Healthcare Professionals only. Select “OK” if you are a US Healthcare Professional.
OK
Cancel

APPROVED USES

Adalimumab-fkjp is a prescription medicine used:

  • To reduce the signs and symptoms of:
    • Moderate to severe rheumatoid arthritis (RA) in adults. Adalimumab-fkjp can be used alone, with methotrexate, or with certain other medicines. Adalimumab-fkjp may prevent further damage to your bones and joints and may help your ability to perform daily activities.
    • Moderate to severe polyarticular juvenile idiopathic arthritis (JIA) in children 2 years of age and older. Adalimumab-fkjp can be used alone or with methotrexate.
    • Psoriatic arthritis (PsA) in adults. Adalimumab-fkjp can be used alone or with certain other medicines. Adalimumab-fkjp may prevent further damage to your bones and joints and may help your ability to perform daily activities.
    • Ankylosing spondylitis (AS) in adults.
    • Moderate to severe hidradenitis suppurativa (HS) in adults.
      • To treat moderate to severe Crohn’s disease (CD) in adults and children 6 years of age and older.
      • To treat moderate to severe ulcerative colitis (UC) in adults. It is not known if adalimumab products are effective in people who stopped responding to or could not tolerate TNF-blocker medicines.
      • To treat moderate to severe chronic plaque psoriasis (Ps) in adults who are ready for systemic therapy or phototherapy and are under the care of a doctor who will decide if other systemic therapies are less appropriate.
      • To treat non-infectious intermediate (middle part of the eye), posterior (back of the eye), and panuveitis (all parts of the eye) in adults.